The American journal of hospice & palliative care
August 28, 2026
Krishna Hanubal, Akul Munjal, Jino Park et al.
PurposeDespite most psychedelic substances remaining Schedule I, clinical research exploring psychedelic-assisted therapy (PAT) in oncology is expanding. We sought to assess oncology providers' attitudes toward and understanding of PAT.MethodsWe conducted a cross-sectional survey of healthcare professionals involved in oncology across five academic institutions in California, South Carolina,...
August 28, 2026
Holly Hepburn
Renewed clinical interest in psychedelics has drawn attention to their challenging effects, yet most phenomenological and psychometric work derives from psilocybin, leaving cross-substance variation underexplored. This thesis employed codebook thematic analysis to examine challenging experiences across DMT, psilocybin, MDMA, and ketamine, utilising 146 naturalistic accounts collected from...
European Journal of Drug Metabolism and Pharmacokinetics
August 28, 2026
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Nature Communications
August 27, 2026
Chenchen Song, Tinya Chang, Tobias Buchborn et al.
Psilocybin, a psychoactive compound contained in certain mushrooms, can provoke profound psychedelic experiences and also exerts established and controversial therapeutic efficacy in clinical depression and other neuropsychiatric conditions respectively. Here we report that a single systemic administration of the serotonergic psychedelic psilocybin can durably promote social behaviour in the...
Health Affairs Scholar
August 27, 2026
Danielle R Adams, Morgan Hartman, Lisa Gong et al.
Abstract Introduction Oregon is the first US state to permit supervised psilocybin services through a nonmedical, wellness-based model. We examined what prospective clients with psychiatric histories encounter when contacting service centers, including how staff communicate about safety, eligibility, and cost. Methods We conducted a mystery shopper study of 26 licensed service centers in Oregon...
bioRxiv (Cold Spring Harbor Laboratory)
August 27, 2026
Chloe L. West, Bradley Baker, Annabel Duran et al.
preprint
Abstract Background Serotonergic psychedelics show promise for treating psychiatric disorders, with symptom improvements lasting for weeks after a single dose. Clarifying the neural basis of these effects would benefit from an identification of empirical biomarkers of such lasting shifts in brain function. Resting state EEG offers a rapid (<5 minute), low-cost window into functional brain...
Psychopharmacology
August 27, 2026
Frederick S. Barrett, David Wolinsky, Zach Daily et al.
RATIONALE: Delta-9-tetrahydrocannabinol (Δ9-THC) has been reported to evoke psychedelic-like experiences at high doses in some individuals. However, the doses of Δ9-THC that occasion such effects and the phenomenology of these experiences are poorly understood. OBJECTIVES: This brief report presents preliminary findings from a pilot human laboratory study that directly compared the acute...
bioRxiv (Cold Spring Harbor Laboratory)
August 25, 2026
Roberto De Filippo, Ryan Gillis, David G Wyrick et al.
preprint
Abstract Psilocybin profoundly alters visual perception, yet the neuronal mechanisms underlying these effects remain unclear. Here we combined large-scale Neuropixels recordings with cell-type-specific optogenetics in head-fixed mice performing a visual change-detection task. Psilocybin severely impaired task performance without overt motor deficits. In cortex, the drug modestly suppressed...
Journal of Psychopharmacology
August 25, 2026
Praachi Tiwari, Bryan W. Jenkins, Catherine F Moore et al.
Psychedelics have emerged as promising pharmacological agents for treating a range of neuropsychiatric disorders. While preclinical studies have provided valuable insight into the neural mechanisms underlying their effects, systematic characterization of psychedelic effects on inherent spontaneous behaviors in animal models remains limited. In the current study, male and female Sprague-Dawley...
medRxiv
August 22, 2026
Tobias P. Whelan, Mihail Dimitrov, Lucas G. S. França et al.
preprint
Importance There is increasing interest in the potential of psilocybin to treat mental health and neurodevelopmental conditions. At high doses, the therapeutic benefit of psilocybin is linked to greater functional connectivity or integration between large-scale brain networks which underpin mood, emotion and cognition. However, it is unknown how the brain responds to psilocybin in autism - a...
Nature Medicine
August 21, 2026
The trials of translating psilocybin treatment from research to practice.
Mental Health Weekly
August 21, 2026
Valerie A. Canady
Given the growing interest in psychedelic‐assisted therapies, questions remain about how such services perform outside controlled clinical trials. A new JAMA Network Open study offers an early look at the risks and benefits of Oregon's state‐regulated psilocybin program, which researchers describe as the first study of its kind in the nation.
Acad Forensic Pathol
August 21, 2026
Complex Fatal Self-Harm Under Psilocybin Intoxication: Suicidal Manner of Death or Not?
bioRxiv
August 20, 2026
Ilknur Kayikcioglu Bozkir, Ryan Lashin, Tiecheng Liu et al.
preprint
Psilocybin is a psychedelic which has been shown to induce neural plasticity through activation of intracellular serotonergic 5-HT2A receptors. It also produces brain-wide changes in structural and functional connectivity and holds promise as a therapeutic compound for treating anxiety and depression. Despite links between psilocybin-induced plasticity, the psychedelic experience, and reduction...
Lynchburg Journal of Medical Science
August 20, 2026
Rachel N Clark
The purpose of this review is to evaluate the possible benefits of using psilocybin (C12H17N2O4P), a naturally occurring psychoactive compound found in certain species of mushrooms, in the treatment of multiple forms of mental illness and substance use disorders, either as monotherapy or in conjunction with traditional psychiatric medications. The compound has high affinity for several...
medRxiv
August 19, 2026
Harland V. Harrison, Maxence Gaillard, Ryan Cook et al.
preprint
Introduction: In 2020, Oregon became the first US state to legalize state-regulated psilocybin services. This study aims to examine: 1) the clinical and demographic characteristics, 2) psilocybin use motivations, and 3) differences in preparedness among patients seeking care in a Oregon- based pilot consult service specializing in psilocybin risk reduction. Methods: This retrospective chart...
bioRxiv
August 19, 2026
D. Momi, Yasmeen Nahas, D. Wyrick et al.
preprint
Psilocybin produces rapid and lasting therapeutic effects, yet how 5-HT2A receptor activation reshapes brain-wide circuit dynamics during acute drug administration remains poorly understood. Using simultaneous multi-region Neuropixels recordings of 46,360 single units from 35 mice, together with scalp electroencephalography (EEG), pupillometry, and locomotion monitoring, we provide a...
Frontiers in Psychiatry
August 19, 2026
Jeni Page, Alexandra Moore, Bridget E. Hawkins et al.
IntroductionMicrodosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing...
August 18, 2026
Ximena A. Levander, Ryan Cook, Devin Gregoire et al.
preprint
There has been growing public and research interest in the use of psychedelics, particularly psilocybin. There is limited data on psilocybin use patterns, motivations for use, safety, and efficacy in older adults (>or= 60 years old) as older adults tend to be excluded from clinical trials. However, older adults may seek out psilocybin through state-regulated or naturalistic settings for...
Journal of Psychopharmacology
August 17, 2026
Lana Strika-Bruneau, Chérine Elhssaini, Baptiste Fauvel et al.
Background: Psychedelic-assisted psychotherapy (PAP) shows promise for substance use disorders (SUDs), yet the respective contributions of pharmacological, experiential, psychotherapeutic, and contextual factors remain insufficiently understood. Objective: To synthesize contemporary clinical evidence on PAP for SUDs, with particular attention to therapeutic frameworks, dosing strategies,...